Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ablynx NV

Division of Sanofi
www.ablynx.com

Latest From Ablynx NV

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom

A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.

M & A Leadership

Q4 Pharma Earnings Preview: GSK, Lilly, Sanofi And AstraZeneca

GlaxoSmithKline will update investors on strategy after completing its Tesaro acquisition. Lilly may have guidance updates following its Loxo acquisition and Lartruvo setback news. Sanofi investors await a pair of new approvals, and AstraZeneca faces investors for the first time since the departure of Chief Medical Officer Sean Bohen and establishing a new organizational structure.

Sales & Earnings Business Strategies

2018’s Top Biopharma Deal-makers

Even though 2018 did not feature the big influx of biopharma M&A that was expected, there were still encouraging signs that major advancements and breakthroughs in the biotech industry attract buy-outs. Cancer-focused companies and oncology assets again drove volume in alliances and financing transactions.

Deals Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Edwin Moses, PhD, CEO
    Wim Ottevaere, CFO
    Markus Ewert, PhD, CBO
    Robert K Zeldin, MD, CMO
    Heylen Johan, Chief Commerical Officer
    Robert Friesen, PhD, CSO
  • Contact Info
  • Ablynx NV
    Phone: (32) 9 262 00 00
    Technologiepark 21
    Ghent/Zwijnaarde, 9052
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register